Muelheim an der Ruhr, Germany

Miles Aukland

This inventor holds 1 USPTO granted patent. Top assignee: Studiengesellschaft Kohle Mbh. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Miles Aukland. Retrieved from https://idiyas.com/inventor/miles-aukland

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Miles Aukland and Catalytic Glycosylation of Arenes.

Introduction

Miles Aukland is an inventor associated with Mülheim an der Ruhr, Germany. His patent work includes a process for catalytic glycosylation of arenes, a method with potential applications in the synthesis of nucleoside compounds.

Latest Patents

Aukland is named on 1 patent: “Process for the Catalytic Glycosylation of Arenes.” The invention describes a catalytic process for glycosylating arenes and notes that it can enable the efficient synthesis of GS-441524, a nucleoside analogue used in the development of the antiviral prodrug remdesivir.

Career Highlights

Aukland is associated with Studiengesellschaft Kohle mbH. His patent reflects research into catalytic chemistry and methods for preparing compounds relevant to pharmaceutical development.

Collaborations

Aukland’s listed coworkers include Benjamin List and Carla Obradors. Their names connect his work with a broader research environment focused on chemical synthesis and catalysis.

Conclusion

Miles Aukland’s patent on catalytic glycosylation of arenes highlights a chemistry innovation with relevance to the synthesis of GS-441524 and related pharmaceutical research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…